Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Sankyo And ArQule Reach Phase I In First Kinase Inhibitor Of Multi-target Discovery Deal

This article was originally published in PharmAsia News

You may also be interested in...



Daiichi Sankyo And ArQule Expand Collaboration On Heels Of Positive ARQ 197 News

TOKYO - Daiichi Sankyo and ArQule announced a flurry of activity surrounding their oncology collaboration, including regulatory and clinical updates for c-Met inhibitor ARQ 197 and expansion of their drug discovery program based on ArQule kinase inhibitor platform (AKIP) technology

FCPA In The China Framework Warrants Special Attention

The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?

Astellas Regains Japan Losses With Xtandi Expansion

Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.

Topics

Related Companies

UsernamePublicRestriction

Register

SC076662

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel